Literature DB >> 7640637

Behavioral effects of intra-amygdala injections of GABA and 5-HT acting drugs in the elevated plus-maze.

H Zangrossi Júnior1, F G Graeff.   

Abstract

The effect of drugs bilaterally injected into the basolateral/medial nuclei of the amygdala on the behavior of male Wistar rats (300-330 g) in the elevated plus-maze was measured. The benzodiazepine agonist midazolam (MDZ, 20 and 40 nmol, 0.2 microliters; N = 8-14) significantly increased open-arm exploration (% open-arm entries: control = 20.27 +/- 3.71; 40 nmol MDZ = 42.63 +/- 7.16), having thus an anxiolytic effect. On the contrary, the non-selective 5-HT2 antagonist ketanserin (KET, 1 and 10 nmol, 0.2 microliters; N = 8-11) had an anxiogenic effect (% open-arm entries: control = 35.61 +/- 6.41; 10 nmol KET = 18.65 +/- 3.89). The 5-HT1A full agonist 8-OH-DPAT (2, 4, and 8 nmol, 0.2 microliters; N = 9-12) did not significantly change rat behavior in the plus-maze. While the present anxiolytic effect of midazolam agrees with results reported by others using punished behavior, the effect of the serotonergic drugs does not. Therefore, the effect of 5-HT acting drugs injected into the amygdala may be determined by the type of experimental model of anxiety used.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7640637

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  10 in total

1.  A novel subpopulation of 5-HT type 3A receptor subunit immunoreactive interneurons in the rat basolateral amygdala.

Authors:  F Mascagni; A J McDonald
Journal:  Neuroscience       Date:  2006-12-05       Impact factor: 3.590

2.  Neuronal localization of 5-HT type 2A receptor immunoreactivity in the rat basolateral amygdala.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2007-02-28       Impact factor: 3.590

3.  Strychnine and taurine modulation of amygdala-associated anxiety-like behavior is 'state' dependent.

Authors:  Brian A McCool; Ann Chappell
Journal:  Behav Brain Res       Date:  2007-01-17       Impact factor: 3.332

4.  Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.

Authors:  N Salomé; J Stemmelin; C Cohen; G Griebel
Journal:  Psychopharmacology (Berl)       Date:  2006-06-02       Impact factor: 4.530

5.  Behavioral effects of systemically administered MK-212 are prevented by ritanserin microinfusion into the basolateral amygdala of rats exposed to the elevated plus-maze.

Authors:  Antonio Pedro de Mello Cruz; Gilson Pinheiro; Sérgio Henrique Alves; Graziela Ferreira; Marília Mendes; Letícia Faria; Carlos Eduardo Macedo; Vitor Motta; J Landeira-Fernandez
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Anxiolytic effects of 5-HT₁A receptors and anxiogenic effects of 5-HT₂C receptors in the amygdala of mice.

Authors:  Qian Li; Tian Luo; Xue Jiang; Jing Wang
Journal:  Neuropharmacology       Date:  2011-09-14       Impact factor: 5.250

Review 7.  Oxytocin interactions with central dopamine and serotonin systems regulate different components of motherhood.

Authors:  Zachary A Grieb; Joseph S Lonstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2022-07-11       Impact factor: 6.671

Review 8.  Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease.

Authors:  Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2008-03-26       Impact factor: 8.989

Review 9.  Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex.

Authors:  Cristiano Bombardi
Journal:  Front Pharmacol       Date:  2014-04-09       Impact factor: 5.810

10.  Lateral/basolateral amygdala serotonin type-2 receptors modulate operant self-administration of a sweetened ethanol solution via inhibition of principal neuron activity.

Authors:  Brian A McCool; Daniel T Christian; Jonathan A Fetzer; Ann M Chappell
Journal:  Front Integr Neurosci       Date:  2014-01-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.